News - Bavarian Nordic
WEBSep 12, 2024 · August 16, 2024 | Press Releases. Bavarian Nordic Submits Data to EMA to Extend Mpox/Smallpox Vaccine Approval to Adolescents. August 13, 2024 | Company Announcements. Bavarian Nordic Receives Order from HERA and Announces Significant Donation of Vaccines in Response to the Mpox Outbreak in Africa.
Bavarian Nordic
WEBSeptember 13, 2024. Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine. September 12, 2024. Bavarian Nordic Provides Update on the Mpox Vaccine Supply Situation. September 05, 2024. First Doses of Bavarian Nordic’s Mpox Vaccine Now Arriving in the Democratic Republic of Congo. View more. Job …
Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical …
WEBSep 2, 2022 · COPENHAGEN, Denmark, September 2, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today the dosing of the first subject in the Phase 3 clinical trial of ABNCoV2, a VLP-based, non-adjuvanted ...
News | Bavarian Nordic
WEBJun 10, 2022 · News | Bavarian Nordic. Bavarian Nordic Receives an Additional Order for JYNNEOS Smallpox and Monkeypox Vaccine from the U.S. Government. BARDA has ordered 500,000 doses of liquid-frozen JYNNEOS ® to be manufactured from existing bulk vaccine for delivery in 2022.
Mpox vaccine maker Bavarian Nordic seeks ‘critical’ approval
WEBAug 16, 2024 · Bavarian Nordic seeks ‘critical’ mpox vaccine approval for teens, CEO says. Should the EMA clear the vaccine for use for teenagers, the company said it would pave the way for approval among ...
One Bavarian Nordic Shot 58% Effective Against Mpox, Study …
WEBSep 11, 2024 · Photographer: Jill Connelly/Bloomberg (Jill Connelly/Bloomberg) (Bloomberg) -- Bavarian Nordic A/S’s smallpox vaccine was moderately effective in preventing mpox infection after a single dose, according to a study in Ontario, Canada, where the shot probably helped curb a 2022 outbreak. One vaccination provided about 58% protection against ...
Bavarian Nordic raises outlook for third time buoyed by U.S.
WEBJun 10, 2022 · Bavarian Nordic raised its financial guidance for 2022 for the third time in a month on Friday after receiving a large order for its monkeypox vaccine by the U.S. Biomedical Advanced Research...
Bavarian Nordic in pact with global vaccine group, Gavi for 500K …
WEBGavi, the global vaccine alliance, announced Wednesday an advance purchase agreement with Bavarian Nordic (OTCPK:BVNKF) to procure 500,000 doses of the Danish biotech’s FDA-approved MVA-BN mpox ...
Bavarian Nordic Provides Update on the Phase 3 Program for its …
WEBJun 16, 2022 · BVNRY. Bavarian Nordic A/S. Phase 3 trial of ABNCoV2, a non-adjuvanted COVID-19 booster vaccine candidate, has been redesigned as comparator vaccine has now become available, enabling a...
News | Bavarian Nordic
WEBJun 27, 2023 · Bavarian Nordic Reports Phase 3 Topline Results for its COVID-19 Booster Vaccine Candidate. Booster study successfully met its primary objective, demonstrating non-inferiority to mRNA-vaccine; Regulatory pathway will depend upon the outcome of secondary endpoints, reporting in the third quarter of 2023